

Applicants: Tikva Vogel et al.
Serial No.: 09/492,971
Filed: January 27, 2000
Page 3

3. U.S. Patent No. 4,587,122 to Kagitani et al., issued May 6, 1986;
4. U.S. Patent No. 4,663,146 to Morser and Shuman, issued May 5, 1987;
5. U.S. Patent No. 4,839,464 to McCarthy et al., issued June 13, 1989;
6. U.S. Patent No. 5,026,537 to Daddona et al., issued June 25, 1991;
7. U.S. Patent No. 5,270,030 to Vogel et al., issued December 14, 1993;
8. U.S. Patent No. 5,455,158 to Vogel et al., issued October 3, 1995; (**Exhibit 1**)
9. U.S. Patent No. 5,679,320 to Vogel et al., issued October 21, 1997; (**Exhibit 2**)
10. U.S. Patent No. 5,869,616 to Vogel et al., issued February 9, 1999; (**Exhibit 3**)
11. U.S. Patent No. 5,965,383 to Vogel et al., issued October 12, 1999; (**Exhibit 4**)
12. Abstract of Japanese Patent Application No. JP 1261398, filed October 18, 1989;
13. European Patent Application No. 0 207 751 A1, published July 1, 1987;
14. PCT International Publication No. WO 89/00051, published

Applicants: Tikva Vogel et al.
Serial No.: 09/492,971
Filed: January 27, 2000
Page 4

January 12, 1989;

15. Garcia-Pardo et al., *J. of Biol. Chem.*, **258**:12670-12674 (1983);
16. Hynes and Yamada, *J. of Cell Biology*, **95**:369-377 (1982);
17. Mosher and Procter, *Science*, **209**:927-929 (1980);
18. Savill et al., *Anticancer Res.*, **6**:315-320 (1986);
19. Uehara et al., *J. of Nuclear Medicine*, **29**:1264-1267 (1988);
and
20. Wieiblen et al., *J. Immunol. Methods*, **58**:73-81 (1983).

The subject application is a continuation of U.S. Serial No. 08/909,140, filed August 11, 1997, which is a divisional of U.S. Serial No. 08/409,750, filed March 24, 1995, which is a continuation of U.S. Serial No. 08/058,241, filed May 4, 1993, now U.S. Patent No. 5,455,158, issued October 3, 1995; which is a divisional of U.S. Serial No. 07/526,397, filed May 21, 1990, now U.S. Patent No. 5,270,030, issued December 14, 1993; which is a continuation-in-part of U.S. Serial No. 07/345,952, filed April 28, 1989, now abandoned; which was a continuation-in-part of U.S. Serial No. 07/291,951, filed December 29, 1998, now abandoned and claiming priority of Canadian Patent Application No. 2,006,929-5, filed September 29, 1989.

Copies of references 1-7 and 12-20 have previously been submitted to the U.S. Patent and Trademark Office in an Information Disclosure Statement in connection with prior application U.S. Serial No. 08/409,750.


Applicants: Tikva Vogel et al.
Serial No.: 09/492,971
Filed: January 27, 2000
Page 5

The references listed hereinabove are also listed on attached PTO Form 1449 (**Exhibit A**).

Applicants request that the Examiner review the references and make them of record in the subject application.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided.

No fee is deemed necessary in connection with the filing of this Second Preliminary Amendment and Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.



Respectfully submitted,

John P. White
Registration No. 36,479
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Assistant Commissioner for Patents,
Washington, D.C. 20231.

6/16/00

John P. White Date
Reg. No. 28,678